Will the FDA approve ivonescimab (HARMONi BLA) by the November 14, 2026 PDUFA date?

The FDA's explicit requirement for statistically significant OS benefit is the critical barrier. The BLA is based on PFS data from China-centric trials. Even with positive PFS from HARMONi-3, interim OS data must be available and favorable by November. The bispecific antibody class has no prior non-China Phase III approvals. Historical base rate for novel biologics with PFS-only data and explicit OS requirement is well below 50%.

The gap between FDA's stated requirement (OS) and available evidence (PFS) is the dominant factor. Interim OS data is guided for H2 2026 but may come after the PDUFA date. The FDA statement was unambiguous. Even if PFS data from HARMONi-3 is positive, the OS hurdle creates a high barrier to outright approval by November.

Several factors lean slightly more positive: four positive Phase III trials show consistent PFS benefit; management has been accelerating timelines (added interim PFS to protocol); insider conviction is extraordinary. The FDA may accept a strong PFS benefit combined with an OS trend even if not yet statistically significant. Accelerated approval pathways exist for oncology.

The FDA was explicit about needing OS. This is not ambiguous language — they said statistically significant OS is necessary. The BLA was accepted (standard procedure if application is complete), but acceptance does not equal approval. Base rate for novel biologics meeting explicit FDA OS requirements with only PFS data on file is approximately 25-35%.

The bullish case rests on three factors: (1) the oncology division has used accelerated approval based on PFS before, (2) ivonescimab addresses a massive unmet need with a novel mechanism, and (3) interim OS data may show a favorable trend by PDUFA. Management's aggressive commercial readiness suggests internal confidence. But the explicit OS statement makes outright approval unlikely without positive OS data.

Taking the FDA at face value: they said OS is necessary. Without statistically significant OS data by November 14, the most likely outcome is a Complete Response Letter requesting additional OS follow-up. The timeline for OS maturity makes this very difficult to achieve. Low confidence because FDA decision-making can be unpredictable.

FDA requires OS. Current data is PFS. Four positive trials but China-centric. OS timing uncertain. Slightly above base rate due to strong PFS data and accelerated approval precedent in oncology.

Bispecific antibody with no non-China approval precedent. FDA explicit about OS. Timeline is tight for OS data before PDUFA. Most likely a CRL with request for more OS data.

Strong insider conviction and management's commercial readiness suggest internal knowledge of positive OS trends. Multiple positive trials add weight. But FDA's explicit statement is hard to overcome without OS data in hand.